Navigation Links
FDA Permits Marketing of the First Hand-Held Device To Aid in the Detection of Bleeding In The Skull
Date:12/13/2011

SILVER SPRING, Md., Dec. 13, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today allowed marketing of the first hand-held device intended to aid in the detection of life-threatening bleeding in the skull called intracranial hematomas, using near-infrared spectroscopy.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The device, called the Infrascanner Model 1000, can help health care providers identify patients with critical head injuries who need an immediate brain imaging study.

Intracranial hematomas occur when blood from a ruptured blood vessel collects within the brain or between the skull and the brain. As blood expands within the brain or in the narrow space between the brain and the skull, the brain becomes compressed. This can produce symptoms such as headaches, vomiting, dizziness, lethargy, weakness in the arm or leg on one side of the body, seizures, or unconsciousness. An intracranial hematoma can be life-threatening if it is not treated immediately.

According to the Centers for Disease Control and Prevention, each year about 1.7 million people in the United States experience a traumatic brain injury.

The Infrascanner, Model 1000, uses a scanner that directs near-infrared light, a wavelength of light that can penetrate tissue and bone, into the skull. Blood from intracranial hematomas absorbs the light differently than other areas of the brain. The scanner detects differences in light absorption (optical density) and transmits the information wirelessly to a display on a hand-held computer.

By comparing the optical density from a series of scans of specific areas on both sides of the skull, a trained health care provider can use the information provided by the device, in conjunction with other clinical information, to determine the likelihood of an intracranial hematoma and the need for further diagnostic proc
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Permits Marketing of First Test to Help Diagnose Dengue Fever
2. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
3. FDA Permits Marketing of a System to Repair Failed, Problematic Fix for Aortic Aneurysms
4. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
5. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
6. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
7. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
8. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
11. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... UNICANCER pourra identifier ... bénéficier de l,innovation thérapeutique.   ... contenu pour l,Entreprise, annonce que sa solution Luxid® ... de lutte contre le cancer (CLCC), comme module ... (Continuum Soin-Recherche) conduit par la société de conseil ...
(Date:3/5/2015)... 5, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter and full year 2014 financial results will ... the market opens for trading.  At 9:00 am ... call to discuss the financial results and provide ...
(Date:3/5/2015)... 2015  IRIDEX Corporation (Nasdaq: IRIX ) today ... January 3, 2015.  , Revenues were $11.8 million ... Company and up 11% from $10.6 million in the 2013 ... record, up 12% from $38.3 million in 2013. , ... from 48.6% in the fourth quarter of the prior year. ...
Breaking Medicine Technology:TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 2TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 3TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 4Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8
... Hanger Orthopedic Group, Inc. (NYSE: HGR ) ... operations for the quarter ended September 30, 2010, on Wednesday, ... a press release announcing the results for the quarter ended ... close of the market. The conference call is scheduled to ...
... Sept. 30 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) in ... on SymPath(R) and is now ready to give you ... of the Sympathetic Nervous System (SNS). Here is a ... will be available to all patients through their health ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Third Quarter 2010 Earnings Release Conference Call 2A brief explanation of Dopamine-Beta-hydroxylase (DBH) - SymPath(R) : In Vitro Diagnostic Test to distinguish anxious disorders from depressive disorders 2A brief explanation of Dopamine-Beta-hydroxylase (DBH) - SymPath(R) : In Vitro Diagnostic Test to distinguish anxious disorders from depressive disorders 3
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
(Date:3/6/2015)... First Choice Emergency Room opened its new Littleton ... 13351 W. Bowles Avenue, Littleton, Colorado and is open 24-7. ... provide the highest quality emergency medical care to the Littleton ... Emergency Room Littleton. , First Choice Emergency Room ... of Commerce and a medical community open house yesterday. ...
(Date:3/6/2015)... 2015 Jvion, the Atlanta-based leader ... a Clostridium Difficile (C Diff) predictive use case ... use case is the latest in a broad ... infections, chronic conditions, and individual illnesses. Using the ... solution flags at risk individuals to help support ...
(Date:3/6/2015)... Truly Nolen, the largest family-owned pest control ... opening of their first independently-owned and operated franchise in ... Fort Mill – Rock Hill, SC area. The ribbon ... their new location. , The Truly Nolen ... in the pest control industry. Locally owned and operated ...
(Date:3/6/2015)... 2015 In a new study conducted at ... reported that shoulder pain was their first mesothelioma symptom. Surviving ... Click here to read it now. , Doctors ... records of 49 mesothelioma patients between 2006 and ... was shoulder pain that first prompted them to see a ...
Breaking Medicine News(10 mins):Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2
... was supported by the German Research Foundation, brought together scientists ... from the Charit in Berlin. 28 younger persons who had ... equal number of non-smokers participated in this study. Each of ... faces while their brain activity was recorded. The researchers were ...
... logic. But although a computer processor can be dissembled and ... the way our brains process information, says Mark Shein of ... Shein and his supervisors, Prof. Yael Hanein of the School ... of Physics and Astronomy, want to understand the brain,s logic. ...
... has released its global status report on alcohol and ... the discussion in the report of the serious health ... which contributes to accidents, many diseases, and premature deaths. ... that the report was limited almost exclusively to abusive ...
... By Steven Reinberg HealthDay Reporter , MONDAY, July ... comes new research pitting fast food against fruits and veggies, ... found that so-called "food deserts," where there are few or ... to draw locals to the fast food. But in areas ...
... -- Upward social mobility appears to help reduce the risk ... poor or disadvantaged situations, according to a new study. ... at increased risk for high blood pressure, which contributes to ... and socioeconomic data collected from 12,000 same-sex twins who were ...
... presented at the upcoming annual meeting of the Society ... society for research into all aspects of eating and ... promote overeating, weight gain, and insulin resistance. Olanzapine, ... the treatment of schizophrenia and bipolar disorder, has been ...
Cached Medicine News:Health News:Smokers not very receptive to shocking images 2Health News:Cracking the code of the mind 2Health News:Cracking the code of the mind 3Health News:Fast Food Is King of the Neighborhood, Study Reports 2Health News:Fast Food Is King of the Neighborhood, Study Reports 3
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Gold radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
... balloon design allows the ureter to be ... marker at the base of the balloon ... ureteral dilation. Supplied sterile in peel-open packages. ... Vise Handle (plastic), Straight Safety Wire Guide ...
Used retrograde to dilate the ureter and establish a conduit for a flexible ureteroscope. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: